Search

Displaying results 1321 - 1330 of 10000 in total
  1. Pathway

    Cardiolipin Biosynthesis CL(a-13:0/a-21:0/a-25:0/a-15:0)[rac]

    smpdb.ca/view/SMP0369432
    Metabolic

    Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  2. Pathway

    Cardiolipin Biosynthesis CL(a-13:0/a-21:0/a-25:0/a-25:0)[rac]

    smpdb.ca/view/SMP0369435
    Metabolic

    Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  3. Pathway

    Cardiolipin Biosynthesis CL(a-13:0/a-25:0/a-13:0/a-13:0)[rac]

    smpdb.ca/view/SMP0371345
    Metabolic

    Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  4. Pathway

    Cardiolipin Biosynthesis CL(a-13:0/a-25:0/a-13:0/a-25:0)[rac]

    smpdb.ca/view/SMP0371349
    Metabolic

    Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  5. Pathway

    Cardiolipin Biosynthesis CL(a-13:0/a-25:0/a-15:0/a-25:0)[rac]

    smpdb.ca/view/SMP0371367
    Metabolic

    Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  6. Pathway

    Cardiolipin Biosynthesis CL(a-13:0/a-25:0/a-21:0/a-21:0)[rac]

    smpdb.ca/view/SMP0371403
    Metabolic

    Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  7. Pathway

    Cardiolipin Biosynthesis CL(a-13:0/a-25:0/a-21:0/a-25:0)[rac]

    smpdb.ca/view/SMP0371404
    Metabolic

    Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  8. Pathway

    Cardiolipin Biosynthesis CL(a-13:0/a-25:0/a-25:0/a-13:0)[rac]

    smpdb.ca/view/SMP0371418
    Metabolic

    Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  9. Drug

    Zanidatamab

    go.drugbank.com/drugs/DB15471
    ApprovedInvestigational

    Zanidatamab is a bispecific antibody that binds two non-overlapping sites of HER2 (ERBB2). … [A264718] In November 2024, the FDA granted an accelerated approval for zanidatamab for use in previously treated unresectable or metastatic HER2-positive biliary tract cancers.[L51908,L51903]

    Categories: HER2 (Human Epidermal Growth Factor Receptor 2) inhibitorsSynonyms: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY
  10. Drug

    Cisplatin

    go.drugbank.com/drugs/DB00515
    ApprovedInvestigational

    Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung

    Categories: OCT2 Substrates with a Narrow Therapeutic Index, Compounds used in a research, industrial, or household settingSynonyms: (SP-4-2)-DIAMMINEDICHLOROPLATINUM, PLATINUM, DIAMMINEDICHLORO-, (SP-4-2)-